Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar is building a drug development pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical experience to help reduce the risk and accelerate the clinical development of its drug product candidates.

Monopar's team is located in San Francisco, CA and Chicago, IL.

Innovative Drugs and Drug Combinations

Licensing, developing and commercializing transformative oncology therapeutics

Identifying drug candidates that can be developed in combination with approved cancer drugs to mitigate toxicity and improve antitumor efficacy.
Developing new drug combinations to eliminate overlapping toxicity while enhancing antitumor synergies.
Identifying reduced-risked clinical opportunities where existing scientific and clinical data support development of more effective drug combinations without increasing toxicity.

Why Oncology?

Multiple factors drive our passion for oncology

Approximately one in every two individuals will develop cancer during their life.
It is one of the leading causes of death worldwide, and the second leading cause of death in the U.S. It accounts for nearly 1 in every 4 deaths in the U.S.
The increasing implementation of drug combinations is creating a need for new individualized therapies which are specifically designed to work synergistically.
Our team and networks of collaborators are driven by their personal experiences and have deep expertise in translating new treatments for advanced cancer.

Corporate Overview

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization.

Discover

Our Research Pipeline

Monopar’s pipeline consists of Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers.

Product	Indications	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Status
MNPR-101-Zr	Imaging Agent for MNPR-101 RIT	Discovery complete	Preclinical complete	Phase 1 in progress	Phase 2 not started	Phase 3 not started	Phase 1 Clinical Trial Active and Recruiting
MNPR-101 RIT	Advanced Solid Cancers	Discovery complete	Preclinical in progress	Phase 1 not started	Phase 2 not started	Phase 3 not started	Late Preclinical
Early Pipeline	Solid cancers	Discovery complete	Preclinical in progress	Phase 1 not started	Phase 2 not started	Phase 3 not started	Early Preclinical
Early Pipeline	Solid cancers	Discovery in progress	Preclinical not started	Phase 1 not started	Phase 2 not started	Phase 3 not started	Discovery

Email Alerts

Stay informed and receive company updates straight to your inbox

Personalized & Precise

MNPR-101-Zr

MNPR-101 RIT

Early Pipeline

Early Pipeline